Mirum Pharmaceuticals (MEX:MIRM) Beneish M-Score: -1.68 (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
49 GF Score
Price MXN1,256.12
GF Value MXN1,066.40
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Beneish M-Score?

Mirum Pharmaceuticals MEX:MIRM 49 Beneish M-Score is -1.68 as of Aug. 25, 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 49/100 and a GF Value™ of MXN1,066.40. The stock has 5 warning signs investors should review. Among 829 Biotechnology companies, Mirum Pharmaceuticals ranks worse than 69.12% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.68 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Mirum Pharmaceuticals's Beneish M-Score or its related term are showing as below:

MEX:MIRM' s Beneish M-Score Range Over the Past 10 Years
Min: -2.87   Med: -2.06   Max: 10.65
Current: -1.68

During the past 8 years, the highest Beneish M-Score of Mirum Pharmaceuticals was 10.65. The lowest was -2.87. And the median was -2.06.


Mirum Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Beneish M-Score Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.77 -2.06 -2.76 -2.45

Mirum Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 -2.58 -2.45 -1.64 -1.68

MEX:MIRM vs COGT, RYTM, ERAS: Beneish M-Score Comparison

For the Biotechnology subindustry, Mirum Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Beneish M-Score falls into.


MEX:MIRM
49GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Mirum Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.972+0.528 * 0.9664+0.404 * 1.0444+0.892 * 1.2971+0.115 * 1.1009
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9532+4.679 * 0.131193-0.327 * 1.4796
=-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was MXN2,536 Mil.
Revenue was 3075.264 + 2883.104 + 2681.625 + 2439.962 = MXN11,080 Mil.
Gross Profit was 2545.722 + 2363.672 + 2172.712 + 1971.506 = MXN9,054 Mil.
Total Current Assets was MXN11,103 Mil.
Total Assets was MXN18,234 Mil.
Property, Plant and Equipment(Net PPE) was MXN249 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN466 Mil.
Selling, General, & Admin. Expense(SGA) was MXN5,629 Mil.
Total Current Liabilities was MXN3,887 Mil.
Long-Term Debt & Capital Lease Obligation was MXN13,271 Mil.
Net Income was -1173.044 + -14248.628 + -103.173 + 53.29 = MXN-15,472 Mil.
Non Operating Income was -709.633 + -13097.186 + -3.925 + 7.246 = MXN-13,803 Mil.
Cash Flow from Operations was -772.153 + -4125.215 + 109.241 + 727.916 = MXN-4,060 Mil.
Total Receivables was MXN2,012 Mil.
Revenue was 2406.089 + 2282.828 + 2073.349 + 1779.55 = MXN8,542 Mil.
Gross Profit was 1965.091 + 1811.921 + 1598.256 + 1369.874 = MXN6,745 Mil.
Total Current Assets was MXN8,537 Mil.
Total Assets was MXN13,667 Mil.
Property, Plant and Equipment(Net PPE) was MXN191 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN483 Mil.
Selling, General, & Admin. Expense(SGA) was MXN4,553 Mil.
Total Current Liabilities was MXN2,726 Mil.
Long-Term Debt & Capital Lease Obligation was MXN5,965 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2536.387 / 11079.955) / (2011.636 / 8541.816)
=0.228917 / 0.235504
=0.972

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6745.142 / 8541.816) / (9053.612 / 11079.955)
=0.789661 / 0.817116
=0.9664

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11102.973 + 249.084) / 18233.873) / (1 - (8537.122 + 190.608) / 13666.704)
=0.377419 / 0.361387
=1.0444

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=11079.955 / 8541.816
=1.2971

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(483.37 / (483.37 + 190.608)) / (465.553 / (465.553 + 249.084))
=0.71719 / 0.651454
=1.1009

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5629.059 / 11079.955) / (4552.661 / 8541.816)
=0.50804 / 0.532985
=0.9532

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((13270.732 + 3887.428) / 18233.873) / ((5965.411 + 2726.393) / 13666.704)
=0.941005 / 0.635984
=1.4796

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15471.555 - -13803.498 - -4060.211) / 18233.873
=0.131193

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Mirum Pharmaceuticals has a M-score of -1.76 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.68 mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Beneish M-Score of -1.68 as of Aug. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #573 out of 829 companies in the Biotechnology industry, placing it in the top 69.1%.
Is Mirum Pharmaceuticals' Beneish M-Score too high?
Mirum Pharmaceuticals' current Beneish M-Score is -1.68. Based on the distribution chart, Mirum Pharmaceuticals ranks #573 out of 829 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Beneish M-Score compare to COGT and RYTM?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #573 out of 829 companies for Beneish M-Score. This places Mirum Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Beneish M-Score is -1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Beneish M-Score of -1.68. The stock's GF Value™ is MXN1,066.40, compared to a current price of MXN1,256.12 — trading 17.8% above its estimated fair value. The current Beneish M-Score is -1.68. Mirum Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Beneish M-Score is -1.68 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 17.8% above its estimated GF Value™ of MXN1,066.40.

Key valuation signals for MEX:MIRM:

  • Beneish M-Score: -1.68
  • GF Value™: MXN1,066.40 vs. price of MXN1,256.12 (17.8% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
49GF Score

Get the complete analysis for MEX:MIRM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN1,066.40
GF Value